Evidence map›Paper›PMID 42591149›Full record

ArticleFrontiers in immunology2026

Targeted depletion of activated fibroblasts via [

Lin Sun, Zhaohua Li, Dan Fang, Shen Zheng, Hongkui Deng, Rong Mu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lin Sun *Department of Rheumatology and Immunology, Center for Rare Disease, Peking University Third Hospital, Beijing, China.
Zhaohua Li *Department of Rheumatology and Immunology, Center for Rare Disease, Peking University Third Hospital, Beijing, China.
Dan FangDepartment of Rheumatology of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Shen ZhengTianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Hongkui DengDepartment of Cell Biology, School of Basic Medical Sciences, Peking University Stem Cell Research Center, Peking University Health Science Center, Peking University, Beijing, China.
Rong MuDepartment of Rheumatology and Immunology, Center for Rare Disease, Peking University Third Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Fibroblast activation protein (FAP)-targeted radiopharmaceuticals have been widely applied in oncologic imaging and therapy, while their application in pulmonary fibrosis remains underexplored. This study investigated the biodistribution and therapeutic potential of [ Methods: The therapeutic potential of an albumin-binder-conjugated FAPI radiopharmaceutical, [ Results: [ Discussion: This study provides proof-of-concept for FAP-targeted radionuclide therapy in experimental pulmonary fibrosis. Our findings suggest that distinct therapeutic outcomes are accompanied by different local tissue responses following treatment and support further evaluation of stromal-targeted radionuclide therapy for pulmonary fibrosis.

Indexed as

FibroblastsGelatinasesLutetiumMembrane ProteinsPulmonary FibrosisRadioisotopesRadiopharmaceuticalsAnimalsBleomycinDisease Models, AnimalEndopeptidasesFibroblast Activation Protein AlphaMaleMiceMice, Inbred C57BLPositron Emission Tomography Computed TomographyBleomycinEndopeptidasesFibroblast Activation Protein AlphaGelatinasesLutetiumLutetium-177Membrane ProteinsRadioisotopesRadiopharmaceuticalsSerine Endopeptidasesfibroblast activation proteinLutetium-177macrophage polarizationpulmonary fibrosisradiopharmaceuticals

Identifiers

PMID42591149
PMCPMC13461414

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.